Laser Interstitial Thermal Therapy for Posterior Fossa Lesions: A Systematic Review and Analysis of Multi-Institutional Outcomes.
LITT
laser interstitial thermal therapy
neuro-oncology
posterior fossa
systematic review
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
17 Jan 2022
17 Jan 2022
Historique:
received:
05
12
2021
revised:
28
12
2021
accepted:
13
01
2022
entrez:
21
1
2022
pubmed:
22
1
2022
medline:
22
1
2022
Statut:
epublish
Résumé
Laser interstitial thermal therapy (LITT) has emerged as a treatment option for deep-seated primary and metastatic brain lesions; however, hardly any data exist regarding LITT for lesions of the posterior fossa. A quantitative systematic review was performed. Article selection was performed by searching MEDLINE (using PubMed), Scopus, and Cochrane electronic bibliographic databases. Inclusion criteria were studies assessing LITT on posterior fossa tumors. 16 studies comprising 150 patients (76.1% female) with a mean age of 56.47 years between 2014 and 2021 were systematically reviewed for treatment outcomes and efficacy. Morbidity and mortality data could be extracted for 131 of the 150 patients. Death attributed to treatment failure, disease progression, recurrence, or postoperative complications occurred in 6.87% (9/131) of the pooled sample. Procedure-related complications, usually including new neurologic deficits, occurred in approximately 14.5% (19/131) of the pooled sample. Neurologic deficits improved with time in most cases, and 78.6% (103/131) of the pooled sample experienced no complications and progression-free survival at the time of last follow-up. LITT for lesions of the posterior fossa continues to show promising data. Future clinical cohort studies are required to further direct treatment recommendations.
Sections du résumé
BACKGROUND
BACKGROUND
Laser interstitial thermal therapy (LITT) has emerged as a treatment option for deep-seated primary and metastatic brain lesions; however, hardly any data exist regarding LITT for lesions of the posterior fossa.
METHODS
METHODS
A quantitative systematic review was performed. Article selection was performed by searching MEDLINE (using PubMed), Scopus, and Cochrane electronic bibliographic databases. Inclusion criteria were studies assessing LITT on posterior fossa tumors.
RESULTS
RESULTS
16 studies comprising 150 patients (76.1% female) with a mean age of 56.47 years between 2014 and 2021 were systematically reviewed for treatment outcomes and efficacy. Morbidity and mortality data could be extracted for 131 of the 150 patients. Death attributed to treatment failure, disease progression, recurrence, or postoperative complications occurred in 6.87% (9/131) of the pooled sample. Procedure-related complications, usually including new neurologic deficits, occurred in approximately 14.5% (19/131) of the pooled sample. Neurologic deficits improved with time in most cases, and 78.6% (103/131) of the pooled sample experienced no complications and progression-free survival at the time of last follow-up.
CONCLUSIONS
CONCLUSIONS
LITT for lesions of the posterior fossa continues to show promising data. Future clinical cohort studies are required to further direct treatment recommendations.
Identifiants
pubmed: 35053618
pii: cancers14020456
doi: 10.3390/cancers14020456
pmc: PMC8773929
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
World Neurosurg. 2019 Dec;132:e124-e132
pubmed: 31518744
AJNR Am J Neuroradiol. 2015 Nov;36(11):1998-2006
pubmed: 26113069
Clin Exp Metastasis. 2020 Jun;37(3):435-444
pubmed: 32377943
Neurosurg Focus. 2016 Oct;41(4):E4
pubmed: 27690652
World Neurosurg. 2021 Oct 30;:
pubmed: 34728396
J Neurosurg. 2018 May 4;130(3):804-811
pubmed: 29726782
Int J Hyperthermia. 2020 Jul;37(2):84-93
pubmed: 32672117
J Neurooncol. 2004 Mar-Apr;67(1-2):115-21
pubmed: 15072456
World Neurosurg. 2020 Dec;144:94-98
pubmed: 32841795
World Neurosurg. 2020 Jul;139:e345-e354
pubmed: 32298824
J Neurooncol. 2020 Sep;149(3):533-542
pubmed: 33057919
Neurosurgery. 2019 Jul 1;85(1):84-90
pubmed: 29860422
World Neurosurg. 2018 Apr;112:166-177
pubmed: 29410102
Neurosurg Focus. 2016 Oct;41(4):E5
pubmed: 27690660
Cancer Lett. 2020 Oct 1;489:9-18
pubmed: 32504657
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
PLoS Med. 2009 Jul 21;6(7):e1000100
pubmed: 19621070
PLoS One. 2016 Feb 24;11(2):e0148613
pubmed: 26910903
Oper Neurosurg (Hagerstown). 2021 Nov 15;21(6):418-425
pubmed: 34528092
J Clin Neurosci. 2021 Aug;90:238-243
pubmed: 34275556
World Neurosurg. 2018 Sep;117:e146-e153
pubmed: 29883824
Neuro Oncol. 2016 Dec;18(12):1601-1609
pubmed: 27407134
Cancer Imaging. 2019 Oct 15;19(1):65
pubmed: 31615562
J Neurosurg. 2016 Oct;125(4):853-860
pubmed: 26722845
World Neurosurg. 2018 Feb;110:e755-e765
pubmed: 29180082
Acta Neurochir (Wien). 2020 Jul;162(7):1771-1775
pubmed: 32281027
Neuro Oncol. 2021 Sep 1;23(9):1586-1596
pubmed: 33823018
Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):719-729
pubmed: 29413284
J Neurooncol. 2018 Mar;137(1):57-65
pubmed: 29204838
Neuro Oncol. 2017 Apr 1;19(4):558-566
pubmed: 27571883
J Neurosurg. 2018 Dec 21;131(6):1958-1965
pubmed: 30579274
Neurosurgery. 2014 Jun;74(6):658-67; discussion 667
pubmed: 24584138